# CED Cannabis Science Digest: Surgery, Abstinence, and Real-World Driving Signals > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-science-digest-surgery-abstinence-driving-july-2026/ > **Published:** 2026-07-24T13:14:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:28-04:00 > **Clinical Summary:** A cannabis research digest examines surgery outcomes, abstinence biomarkers, and real-world driving with careful evidence limits. --- CED Clinical Relevance #69 Clinically Useful, Evidence-Limited The studies add patient-relevant evidence about perioperative counseling, biological changes during abstinence, and public-safety behavior, but each has important design and sample limitations. Clinical Insight | CED Clinic The shared lesson is that cannabis-related clinical signals depend heavily on context and study design. In 259 ankle-fracture patients, an unadjusted difference in opioid duration disappeared after adjustment. In a small secondary analysis, plasma anandamide changed differently across abstinence and continued-use groups, but the biomarker result does not establish withdrawal mechanisms or treatment targets. In 41 habitual cannabis users, naturalistic driving patterns differed by substance-use condition, but self-report, small samples, and exposure choices limit causal interpretation. These papers support careful history-taking and safety counseling, not categorical predictions about analgesia, abstinence, or impairment. DigestPerioperative CareCannabis AbstinenceDriving SafetyHuman Research Audience Patients, clinicians, caregivers, researchers, and public-health readers evaluating emerging cannabis evidence. Primary Topic Three July 2026 peer-reviewed human studies on perioperative outcomes, endocannabinoid changes during abstinence, and naturalistic driving behavior. Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42495974/) Three peer-reviewed human studies examine perioperative [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) after ankle-fracture surgery, endocannabinoid changes during short cannabis abstinence, and driving behavior after cannabis or alcohol use. The findings are observational or secondary analyses and do not establish treatment efficacy, causation, or a reliable rule for determining driving safety. What This Study Teaches Us Self-reported perioperative [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) was not an independent predictor of opioid duration after ankle-fracture surgery. Plasma anandamide changed in opposite directions in small abstinence and continued-use groups. Naturalistic driving observations suggested context-specific behavior after cannabis, alcohol, or combined use. Why This Matters Patients and clinicians routinely face questions about cannabis around surgery, attempts to stop use, and driving. These studies add useful detail while showing why adjusted analyses, measured outcomes, and uncertainty matter more than a simple cannabis-versus-no-cannabis label. Study Snapshot Post Type [Cannabis Science](https://cedclinic.com/biphasic-effects-of-cannabis/) digest using the canonical CED layout Batch ID 109f4340dc464dc4 Curated Set 3 verified, nonduplicate peer-reviewed human studies Item 1 Ankle-fracture surgery and postoperative opioid use, PMID 42495974 Item 2 Cannabis-tobacco co-use, abstinence, and plasma endocannabinoids, PMID 42492375 Item 3 Naturalistic driving after cannabis or alcohol use, PMID 42492402 Evidence Designs Retrospective observational study, secondary prospective analysis, and naturalistic within-person driving analysis Content Lanes Research Brief, Mechanism Watch, and Safety Signal Related Reading 3 verified CED Clinic internal links Clinical Bottom Line These papers support individualized perioperative assessment, cautious interpretation of abstinence biomarkers, and conservative driving-safety counseling. They do not prove that cannabis changes opioid needs, identify a treatment mechanism, or define when a person is safe to drive. Digest Contents - [Digest Card 1 | Cannabis Use Around Ankle-Fracture Surgery](#digest-card-2-digest-card-1-cannabis-use-around-ankle-fracture-surgery) - [Digest Card 2 | Anandamide During Short Cannabis Abstinence](#digest-card-3-digest-card-2-anandamide-during-short-cannabis-abstinence) - [Digest Card 3 | Cannabis, Alcohol, and Naturalistic Driving](#digest-card-4-digest-card-3-cannabis-alcohol-and-naturalistic-driving) Why These Studies Belong Together Each study examines cannabis in a real clinical or behavioral context rather than testing a cannabinoid treatment. Together they show how adjustment, comparison groups, and outcome selection can change the meaning of an apparent cannabis-related signal. Digest Card 1 | [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) Around Ankle-Fracture Surgery Authors / source / date / lane: Harrison Volaski and colleagues, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, electronically published July 23, 2026, Research Brief. PMID 42495974; DOI 10.5435/JAAOSGlobal-D-25-00250. What was investigated: postoperative pain, opioid prescription duration, and complications among 259 adults undergoing ankle-fracture open reduction and internal fixation; 79 reported perioperative cannabis use. Apparent findings: cannabis users had slightly longer unadjusted opioid use, 4.51 versus 4.08 weeks, but cannabis use was not independently associated with opioid duration after adjustment for smoking, sex, and age. Pain scores, opioid dosage, and complications did not differ. Limitations and uncertainty: cannabis exposure was self-reported, groups differed in age, sex, tobacco use, education, and deprivation, and the observational design cannot establish whether cannabis changed outcomes. Why noteworthy: the adjusted null finding adds useful nuance to prior perioperative studies and does not support treating cannabis as a proven standalone postoperative analgesic. Digest Card 2 | Anandamide During Short Cannabis Abstinence Authors / source / date / lane: Sara L. Kroll and colleagues, Drug and Alcohol Dependence, July 21, 2026, Mechanism Watch. PMID 42492375; DOI 10.1016/j.drugalcdep.2026.113277. What was investigated: a secondary analysis compared plasma anandamide and 1-arachidonoylglycerol over two visits in four small groups, including 30 cannabis-tobacco co-users who abstained from cannabis for three days and 18 who continued cannabis while briefly abstaining from nicotine. Apparent findings: anandamide increased in the cannabis-abstinence group and decreased in the continued-cannabis group; 1-arachidonoylglycerol did not differ. Nicotine-only participants and controls were stable. Limitations and uncertainty: the groups were small and unequal, the analysis was secondary, abstinence windows differed by substance, and peripheral biomarkers do not establish brain effects, symptoms, clinical benefit, or a causal mechanism. Why noteworthy: the result provides a human mechanistic signal for future longitudinal work on cannabis abstinence without constituting treatment evidence. Digest Card 3 | Cannabis, Alcohol, and Naturalistic Driving Authors / source / date / lane: Sparsh Jain, Paolo Terranova, Kaitlyn Bedwell, and Miguel Perez, Accident Analysis & Prevention, July 23, 2026, Safety Signal. PMID 42492402; DOI 10.1016/j.aap.2026.108693. What was investigated: personal-vehicle driving data from 41 habitual cannabis users in Washington and Virginia, with trips categorized using pre-drive self-report plus periodic breath and saliva testing. Apparent findings: cannabis-positive trips showed lower highway mileage, 5% less speeding, and possible lane-tracking difficulty. Alcohol-positive trips clustered at night and on weekends, while combined-use trips showed patterns from both conditions. Limitations and uncertainty: the participant sample was small, substance use was not randomized, trip context and route choice could influence behavior, and near-crash events occurred in cannabis-positive and substance-negative drives. Why noteworthy: naturalistic data add real-world context, but the study does not provide a blood or saliva cutoff, a safe waiting period, or proof that any single observed behavior identifies impairment. How Strong Is This Evidence? All three studies are peer-reviewed human investigations with verified PubMed records, publication dates, and identifiers. Their value lies in real-world or clinically relevant observations, not in randomized evidence of treatment efficacy. Where This Paper Deserves Skepticism All three signals are vulnerable to confounding, selection, small-group instability, or measurement limitations. An adjusted null result, a peripheral biomarker change, and a naturalistic behavior pattern answer different questions and should not be combined into a causal narrative. What This Paper Does Not Show The studies do not show that cannabis reduces postoperative pain, prove that cannabis independently prolongs opioid use, establish anandamide as a withdrawal treatment target, or define when cannabis users can drive safely. How This Fits With the Broader Clinical Conversation Cannabis exposure varies by dose, product, route, frequency, tolerance, reason for use, and co-use of nicotine or alcohol. Clinical decisions should incorporate those details and the relevant setting rather than relying on a binary cannabis-use history. Dr. Caplan’s Take *The practical value of these papers is not a new universal rule. It is a reminder to ask better questions about timing, route, co-use, and the outcome that actually matters in the clinical setting.* *For surgery, abstinence, and driving alike, cautious counseling remains appropriate because these studies refine uncertainty more than they resolve it.* What a Careful Reader Should Take Away Use these findings to improve assessment and counseling. Do not translate them into a treatment recommendation, a biomarker diagnosis, or permission to drive. Evidence Interpretation Guide Table of Contents - [How to Read Context-Dependent Cannabis Findings](#How_to_Read_Context-Dependent_Cannabis_Findings)[Four checks for a careful reading](#Four_checks_for_a_careful_reading) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Share the Full Pattern](#Share_the_Full_Pattern) - [Assess the Relevant Context](#Assess_the_Relevant_Context) - [Do Not Assume Opioid Sparing](#Do_Not_Assume_Opioid_Sparing) - [Peripheral Signals Need Validation](#Peripheral_Signals_Need_Validation) - [Use Conservative Safety Advice](#Use_Conservative_Safety_Advice) - [Confounding Remains](#Confounding_Remains) - [Support Clear Planning](#Support_Clear_Planning) - [Connect Signals to Outcomes](#Connect_Signals_to_Outcomes) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read Context-Dependent Cannabis Findings These papers use different designs and measure different outcomes. A careful reading matches each conclusion to the actual comparison and endpoint. ### Four checks for a careful reading **Look for adjustment**An unadjusted difference can disappear after accounting for group differences, as occurred for opioid duration. **Separate biomarker from symptom**A change in plasma anandamide does not by itself establish withdrawal severity, brain function, or a treatment effect. **Account for behavioral context**Naturalistic driving reflects route, timing, substance choice, and other circumstances that controlled trials handle differently. **Avoid universal thresholds**None of these studies identifies a dose, laboratory cutoff, or waiting period that applies safely to every patient. Key Reading Question Did the study measure a clinical outcome, a biological marker, or a behavior, and what alternative explanations remain? The Patient Question What details about my cannabis use, other substances, surgery, symptoms, or planned driving should my clinician know? The Bottom Line Context and design determine how far each finding can responsibly travel. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives on applying observational [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) without overstating certainty. #### Share the Full Pattern Report dose, route, frequency, timing, and co-use of nicotine or alcohol. Those details can matter more than a yes-or-no [cannabis history](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/). Lens takeaway Specific information supports safer counseling. #### Assess the Relevant Context Perioperative planning, abstinence symptoms, and driving safety require different questions. Do not infer one domain from another. Lens takeaway Match assessment to the clinical setting. #### Do Not Assume Opioid Sparing The ankle-fracture study did not find an independent association with opioid duration. It also did not test cannabis as an assigned analgesic. Lens takeaway Plan pain care from measured needs and risk factors. #### Peripheral Signals Need Validation Anandamide changed in small abstinence groups. Clinical meaning requires replication and linkage to symptoms or outcomes. Lens takeaway A biomarker signal is not a treatment result. #### Use Conservative Safety Advice Naturalistic behavior varied by substance condition and context. The study does not identify a reliable safe-to-drive threshold. Lens takeaway Avoid driving when affected or uncertain. #### Confounding Remains Self-selection and group differences can shape observational results. Adjustment improves interpretation but cannot remove every bias. Lens takeaway Association is not causation. #### Support Clear Planning Transportation and perioperative plans are easier to make before risk is immediate. Nonjudgmental questions improve disclosure. Lens takeaway Planning can reduce avoidable harm. #### Connect Signals to Outcomes Future studies need larger samples, verified exposure, longitudinal follow-up, and clinically meaningful endpoints. Randomized designs are needed for treatment claims. Lens takeaway Better measurement is the next step. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CED+Cannabis+Science+Digest%3A+Surgery%2C+Abstinence%2C+and+Real-World+Driving+Signals&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-surgery-abstinence-driving-july-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-surgery-abstinence-driving-july-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=CED+Cannabis+Science+Digest%3A+Surgery%2C+Abstinence%2C+and+Real-World+Driving+Signals%20https%3A%2F%2Fcedclinic.com%2Fcannabis-science-digest-surgery-abstinence-driving-july-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary sources: Volaski et al.; Kroll et al.; Jain et al.](https://pubmed.ncbi.nlm.nih.gov/42495974/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis Use Disorder and Pain Medication After Hand Surgery](https://cedclinic.com/cannabis-use-disorder-postoperative-pain-hand-surgery/) Earlier context from a propensity-matched hand-fracture study that reported higher postoperative analgesic use among patients with documented [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). [Read the perioperative context](https://cedclinic.com/cannabis-use-disorder-postoperative-pain-hand-surgery/) [Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder](https://cedclinic.com/cannabis-co-use-tobacco-cessation-impact-quit-success/) Earlier context on cannabis-tobacco co-use, cessation, and endocannabinoid-system evidence. [Read the co-use context](https://cedclinic.com/cannabis-co-use-tobacco-cessation-impact-quit-success/) [Mobile App Study of Driving Behaviors After Cannabis](https://cedclinic.com/cannabis-driving-impairment-mobile-app-study/) Earlier context on a small real-world driving study and the limits of behavioral detection. [Read the driving context](https://cedclinic.com/cannabis-driving-impairment-mobile-app-study/) ## Frequently Asked Questions Did cannabis independently prolong opioid use after ankle-fracture surgery? No. The unadjusted difference was small, and cannabis use was not independently associated with opioid duration after adjustment for smoking, sex, and age. How many patients were included in the ankle-fracture study? The study included 259 adults, of whom 79 reported perioperative cannabis use. Did the surgery study test cannabis as a pain treatment? No. It observed self-reported perioperative use and did not randomly assign cannabis or test a standardized product or dose. What changed during short cannabis abstinence? Plasma anandamide increased in the small cannabis-abstinence group, while it decreased in a continued-cannabis group that briefly abstained from nicotine. The other measured endocannabinoid did not differ. Does the anandamide finding prove a withdrawal mechanism? No. It is a peripheral biomarker signal from a small secondary analysis and does not establish symptoms, brain effects, or causation. How many people were in the driving study? The naturalistic driving analysis included 41 habitual cannabis users from Washington and Virginia. What did cannabis-positive drives look like? They showed lower highway mileage, a 5% reduction in speeding, and possible lane-tracking difficulty compared with substance-negative drives. Did the driving study identify a safe waiting period? No. It did not establish a universal time, blood level, or saliva level at which driving becomes safe. Do these studies prove cannabis caused the observed differences? No. The studies were observational or secondary analyses and remain vulnerable to confounding, selection, and measurement limitations. What is the practical takeaway? Share detailed cannabis and co-use information with clinicians, plan conservatively around surgery and driving, and treat these findings as emerging evidence rather than treatment proof. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).